Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies

March 15, 2023

Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of fibrosis, today announced a $105M financing, including a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli Lilly & Company, Ono Venture Investment and Mass General Brigham Ventures.

Mediar Announces Simon Sturge as Executive Chairman

September 15, 2021

Mediar Therapeutics today announced Simon Sturge has joined the firm as executive chairman. Sturge brings extensive experience in both large pharmaceutical operations and biopharma startups to Mediar as it advances a novel platform technology focused on the myofibroblast, a cell that is a key driver in fibrosis pathology.

Mediar Therapeutics Welcomes Pfizer Ventures and Ono Venture Investment to its Seed Extension

March 17, 2021

Mediar Therapeutics today announced the completion of a seed extension funding round and welcomed Pfizer Ventures and Ono Venture Investment (OVI) as new syndicate members. Mediar, a discovery-stage company developing new treatments for fibrosis, was co-founded by Mass General Brigham Ventures, formerly Partners Innovation Fund.


March 19 – 23, 2023
Fairmont Banff Springs,
Alberta, Canada

Keystone Symposia on Molecular and Cellular Biology
Fibrosis Pathogenesis and Resolution:
From Mechanisms to Therapies


Keystone Symposia logo

BM Kim et al
WISP1 Neutralization Suppresses Fibrosis in Preclinical in vivo and ex vivo Models
Presented at the Keystone Symposia on Fibrosis Pathogenesis and Resolution: From Mechanism to Therapies

P Yaworsky et al
miR-15a Reprograms Activated Hepatic Stellate Cells Back Towards Quiescence by Targeting WISP1.
Presented at the 3rd International Conference on Tissue Repair, Regeneration, and Fibrosis